술 전 항혈소판제 복합투여가 무심폐기하 관상동맥우회술 후 출혈에 미치는 영향
Effects of Combined Antiplatelets on Bleeding in Off-Pump Coronary-Artery Bypass Surgery
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background Antiplatelet agent administration is critical in managing coronary-artery disease, but there is a concern regarding operation-related bleeding and an increase in blood transfusion in such, especially when delivering combined antiplatelet agents. This study was conducted to evaluate the effect of the administration of antiplatelet agents on off-pump coronary-artery bypass surgery (OPCAB). Methods From March 2003 to December 2009, 49 patients who had undergone OPCAB were collected retrospectively. The patients were divided into three groups according to the administration of antiplatelet agents before the OPCAB operation: 21 patients were given an aspirin agent (group 1), 19 patients were given combined agents (aspirin+clopidogrel) (group 2), and nine patients were not given any antiplatelet agent (group 3). The three groups' perioperative hematologic and coagulation profiles, including their platelet counts, hemoglobin levels, hematocrit, prothrombin times, and aPTTs (activated partial thromboplastin times), and their postoperative bleeding, related complications, transfusion requirements, and operation times, were compared. Results The operation time in group 2 was 4.3 hours, longer than those in the two other groups, and urgent operation was significantly most frequent in group 2 (63%). The amount of blood loss and the number of patients who received blood transfusion were not different in the three groups. The perioperative hemoglobin level, hematocrit, platelet count, prothrombin time, and aPTT were also not significantly different among the three groups. Conclusion The continuous administration of antiplatelet agents to the patients in this study did not increase their postoperative bleeding or operation-related complications. Therefore, OPCAB may well be considered even if combined antiplatelet agents are being administered.
Abstract
Background Antiplatelet agent administration is critical in managing coronary-artery disease, but there is a concern regarding operation-related bleeding and an increase in blood transfusion in such, especially when delivering combined antiplatelet agents. This study was conducted to evaluate the effect of the administration of antiplatelet agents on off-pump coronary-artery bypass surgery (OPCAB). Methods From March 2003 to December 2009, 49 patients who had undergone OPCAB were collected retrospectively. The patients were divided into three groups according to the administration of antiplatelet agents before the OPCAB operation: 21 patients were given an aspirin agent (group 1), 19 patients were given combined agents (aspirin+clopidogrel) (group 2), and nine patients were not given any antiplatelet agent (group 3). The three groups' perioperative hematologic and coagulation profiles, including their platelet counts, hemoglobin levels, hematocrit, prothrombin times, and aPTTs (activated partial thromboplastin times), and their postoperative bleeding, related complications, transfusion requirements, and operation times, were compared. Results The operation time in group 2 was 4.3 hours, longer than those in the two other groups, and urgent operation was significantly most frequent in group 2 (63%). The amount of blood loss and the number of patients who received blood transfusion were not different in the three groups. The perioperative hemoglobin level, hematocrit, platelet count, prothrombin time, and aPTT were also not significantly different among the three groups. Conclusion The continuous administration of antiplatelet agents to the patients in this study did not increase their postoperative bleeding or operation-related complications. Therefore, OPCAB may well be considered even if combined antiplatelet agents are being administered.
참고문헌 (21)
- Angiolillo DJ, "Current antiplatelet therapies: benefits and limitations", Am Heart J, 156(2 Suppl), pp.S3~S9 (2008)
- Lee SW, "Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry)", Am Heart J, 159, pp.284~291 (2010)
- Gurbuz AT, "Postoperative clopidogrel improves mid- term outcome after off-pump coronary artery bypass graft surgery: a prospective study", Eur J Cardiothorac Surg, 29, pp.190~195 (2006)
- Ferraris VA, "Aspirin and postoperative bleeding after coronary artery bypass grafting", Ann Surg, 235, pp.820~827 (2002)
- Klinkhardt U, "Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease", Clin Pharmacol Ther, 73, pp.232~241 (2003)
- Klinkhardt U, "Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb", IIIa inhibitors abciximab and SR121566A, 2000, pp.67, 305~313
- Cannon CP, "Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE trial)", Am J Cardiol, 90, pp.760~762 (2002)
- Duzenli MA, "Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin", Am J Cardiol, 102, pp.396~400 (2008)
- Hekmat K, "The effect of preoperative antiplatelet therapy in coronary artery surgery: blood transfusion requirements for patients on cardiopulmonary bypass", Curr Med Res Opin, 20, pp.1429~1435 (2004)
- Schulze CJ, "Phosphorylcholine-coated circuits improve preservation of platelet count and reduce expression of proinflammatory cytokines in CABG : a prospective randomized trial", J Card Surg, 24, pp.363~368 (2009)
- Tabata S, "Efficacy of FK633, an ultra-short acting glycoprotein IIb", IIIa antagonist on platelet preservation during and after cardiopulmonary bypass, 2004, pp.26, 289~293
- Woolf RL, "Con: heparin-bonded cardiopulmonary bypass circuits do not represent a desirable and cost-effective advance in cardiopulmonary bypass technology", J Cardio- thorac Vasc Anesth, 12, pp.710~712 (1998)
- Totaro P, "Minimally invasive approach for complex cardiac surgery procedures", Ann Thorac Surg, 88, pp.462~466 (2009)
- Ferraris VA, "Society of Thoracic Surgeons. The Society of Thoracic Surgeons practice guideline series: aspirin and other antiplatelet agents during operative coronary revascularization (executive summary)", Ann Thorac Surg, 79, pp.1454~1461 (2005)
- Society of Thoracic Surgeons Blood Conserva- tion Guideline Task Force, "Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline", Ann Thorac Surg, 83(5 Suppl), pp.S27~S86 (2007)
- D'Ancona G, "OPCAB therapy survey: off-pump clopidogrel, aspirin or both therapy survey", Heart Surg Forum, 4, pp.354~358 (2001)
- Mehta SR, "Double- dose versus standard-dose clopidogrel and high- dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT- OASIS 7): a randomised factorial trial", Lancet, 376, pp.1233~1243 (2010)
- Shim JK, "Effects of preoperative aspirin and clopidogrel therapy on perioperative blood loss and blood transfusion requirements in patients undergoing off-pump coronary artery bypass graft surgery", J Thorac Cardiovasc Surg, 134, pp.59~64 (2007)
- Song SW, "Effects of continuous administration of clopidogrel before off-pump coronary artery bypass grafting in patients with acute coronary syndrome", Circ J, 72, pp.626~632 (2008)
- Halkos ME, "Early administration of clopidogrel is safe after off- pump coronary artery bypass surgery", Ann Thorac Surg, 81, pp.815~819 (2006)
- Filsoufi F, "Clopidogrel treat- ment before coronary artery bypass graft surgery increases postoperative morbidity and blood product requirements", J Cardiothorac Vasc Anesth, 22, pp.60~66 (2008)